What is the appropriate management for a 74-year-old female with refractory sleep-maintenance insomnia, dizziness from suvorexant, prior discontinuation of trazodone, mild obstructive sleep apnea, and a low PHQ-9 score?

Pharmacological Management After Doxepin Insurance Denial

Given that eszopiclone 3 mg was previously tried and doxepin 3 mg was denied by insurance, you should immediately trial a different benzodiazepine receptor agonist (BzRA) at the lowest effective dose—specifically zolpidem 5 mg (for women/elderly) or temazepam 7.5-15 mg—while simultaneously pursuing the CBT-I referral and addressing the untreated mild sleep apnea. 1

Rationale for Next-Step Pharmacotherapy

Why BzRAs Remain Appropriate

• Guideline support: The American Academy of Sleep Medicine (AASM) 2017 guidelines suggest using BzRAs (eszopiclone, zolpidem, zaleplon) or benzodiazepines (temazepam, triazolam) for sleep-onset and sleep-maintenance insomnia 1
• Sleep-maintenance insomnia: Your patient's primary complaint is nocturnal awakenings approximately 2 hours after sleep onset, which responds to both zolpidem and temazepam per guidelines 1
• Prior medication failures: Suvorexant caused dizziness and was ineffective; trazodone was discontinued; eszopiclone failed; doxepin was denied—leaving BzRAs as the most evidence-based remaining option

Specific Agent Selection

First choice: Zolpidem 5 mg (start with lower dose given age 74 and female sex)

• Indicated for both sleep onset AND sleep maintenance 1
• Lower fall risk than benzodiazepines in elderly 2
• Can uptitrate to 10 mg if 5 mg ineffective after 1 week
• Critical caveat: FDA black box warning for complex sleep behaviors (sleepwalking, sleep-driving) 2—counsel patient explicitly and document this discussion

Second choice: Temazepam 7.5-15 mg

• Also indicated for sleep onset and maintenance 1
• Longer half-life may better address middle-of-night awakenings
• Higher risk profile: Greater fall risk, cognitive impairment, and dependency potential in elderly 2—use only if zolpidem fails or is contraindicated

Why NOT Other Options

Suvorexant: Already failed with dizziness 3—do not retry even at lower dose given documented adverse effect

Trazodone: Guidelines explicitly recommend AGAINST trazodone for insomnia 1—no difference in sleep efficiency versus placebo, and adverse effect profile outweighs minimal subjective sleep quality improvement 2

Ramelteon: Only effective for sleep-onset insomnia, NOT sleep maintenance 1—inappropriate for this patient's primary complaint of nocturnal awakenings

Benzodiazepines (triazolam): Only indicated for sleep onset, not maintenance 1—and carries higher dependency/fall risk than BzRAs 2

Critical Concurrent Management

Address Untreated Mild Sleep Apnea

The mild sleep apnea is likely contributing significantly to nocturnal awakenings, particularly those "without clear urge to void" 4, 5. This MUST be addressed concurrently with pharmacotherapy:

• Immediate action: Patient should pursue repeat sleep study through PCP as documented in your plan
• Oral appliance: Patient expressed interest—this is appropriate for mild OSA and should be actively facilitated
• Pharmacotherapy consideration: Recent evidence shows lemborexant (another orexin antagonist) and suvorexant do not worsen mild OSA 4, 5, but given suvorexant already failed with dizziness, this is moot

Key point: Treating insomnia pharmacologically without addressing OSA will yield suboptimal results—the OSA treatment is NOT optional

CBT-I Remains Essential

• Strong guideline recommendation: CBT-I is first-line treatment for chronic insomnia 1
• Your patient has failed multiple medications—this makes her an IDEAL candidate for CBT-I
• Virtual sessions are appropriate and effective—ensure front desk completes referral urgently
• Pharmacotherapy should be viewed as bridge therapy while CBT-I is initiated and takes effect (typically 4-8 weeks)

Dosing Algorithm

1. Start zolpidem 5 mg nightly (take within 30 minutes of bedtime, with ≥7 hours remaining before planned awakening)
2. Reassess after 1 week:
   • If effective with good tolerability → continue at 5 mg
   • If ineffective but well-tolerated → increase to 10 mg
   • If adverse effects (morning grogginess, dizziness, complex sleep behaviors) → discontinue and switch to temazepam 7.5 mg
3. Plan for time-limited use: Target 4-6 weeks maximum while CBT-I takes effect 2
4. Taper when discontinuing: Reduce dose by 50% for 1 week, then discontinue to minimize rebound insomnia

Safety Counseling (Document This Discussion)

For Zolpidem Specifically:

• Complex sleep behaviors: Risk of sleepwalking, sleep-driving, preparing/eating food while not fully awake 2
• Next-day impairment: May impair driving even if patient feels fully awake—avoid driving until response known
• Avoid alcohol: Additive CNS depression 2
• Take on empty stomach: Food delays absorption and reduces efficacy 3

For All BzRAs in Elderly:

• Fall risk: Particularly with nighttime bathroom trips (relevant given nocturia)—consider bedside commode
• Cognitive effects: May worsen if patient has any baseline cognitive impairment
• Dependency potential: Use lowest effective dose for shortest duration 2

Common Pitfalls to Avoid

1. Do not combine BzRAs with other sedatives without dose reduction 3
2. Do not ignore the OSA component—pharmacotherapy alone will be inadequate
3. Do not continue ineffective medication "just to try something"—if no improvement after 2 weeks at maximum dose, switch agents
4. Do not delay CBT-I referral—this should happen immediately, not after medication trials
5. Do not use antihistamines (diphenhydramine) as alternative—guidelines recommend against this in elderly due to anticholinergic effects 2, 1

Insurance Considerations

If zolpidem is also denied:

• Generic availability: Zolpidem and temazepam are both generic and typically inexpensive
• Prior authorization: May be needed—document multiple medication failures (suvorexant, trazodone, eszopiclone, doxepin) to support medical necessity
• Alternative if all BzRAs denied: Consider ramelteon 8 mg (melatonin agonist) despite being less ideal for maintenance insomnia, as it has favorable safety profile in elderly 1—but set realistic expectations that it may only partially address symptoms